FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1816122400> ?p ?o ?g. }

• W1816122400 endingPage "42" @default.
• W1816122400 startingPage "4837" @default.
• W1816122400 abstract "We performed a phase I trial of cyclosporin A (CsA) in combination with doxorubicin (dox) to determine the maximally tolerated dose (MTD) of the combination in man, to define the quantitative and qualitative toxicities of the combination, and to determine the pharmacokinetics of the two drugs when used together. CsA was administered as a continuous infusion for 6 days, and dox was administered as a single 10-min infusion 24 h after the initiation of CsA. The starting CsA infusion rate was 5 micrograms/kg/min, and the dox starting dose was 30 mg/m2. Courses were administered every 4 weeks with first CsA and then dox being escalated in consecutive cohorts of patients until the MTD was determined. Twenty-three patients and 40 courses were evaluable for toxicity. Pharmacokinetic analysis was performed in 23 patients on the first course for whole blood CsA and plasma dox and doxorubicinol. The MTD of CsA was 6 micrograms/kg/min, and for dox it was 45 mg/m2. Dose-limiting toxicity was neutropenia. Serum creatinine and creatinine clearance did not change over the infusion period. Bilirubin increased from a median of 10 mumol/liter at the initiation of the infusion to a median of 40.4 mumol/liter at the end of the infusion but returned to normal before the next cycle of therapy. Nausea and vomiting were common and marked, whereas thrombocytopenia was mild. Two patients, one with small cell lung cancer and one with breast cancer, had stable disease while receiving treatment for 5 and 6 months, respectively. Mean whole blood steady state concentrations of CsA were 2210 ng/ml during the infusion with total body clearance of 0.177 liter/h/kg. The area under the concentration x time curve (AUC) increased linearly with dose of dox, and total body clearance was independent of dose. The mean total body clearance was 2.46 liters/h/m2, and terminal half-life was 49.6 h. The AUC for dox was greater and clearance was less than has been previously reported at the doses administered in this study. The ratio of AUC for doxorubicinol to AUC for dox was less than expected, suggesting that the metabolism and/or excretion of dox was decreased when administered with CsA. We conclude that dox can be combined with infusioned CsA but at a lower dose than when given alone. This may be due to altered metabolism and/or excretion of dox or increased bone marrow stem cell sensitivity to dox." @default.
• W1816122400 created "2016-06-24" @default.
• W1816122400 creator A5001359178 @default.
• W1816122400 creator A5003643368 @default.
• W1816122400 creator A5022511085 @default.
• W1816122400 creator A5028260119 @default.
• W1816122400 creator A5033181043 @default.
• W1816122400 creator A5035759347 @default.
• W1816122400 creator A5057832019 @default.
• W1816122400 creator A5063272996 @default.
• W1816122400 creator A5072098734 @default.
• W1816122400 date "1993-10-15" @default.
• W1816122400 modified "2023-09-23" @default.
• W1816122400 title "Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin." @default.
• W1816122400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8402670" @default.
• W1816122400 hasPublicationYear "1993" @default.
• W1816122400 type Work @default.
• W1816122400 sameAs 1816122400 @default.
• W1816122400 citedByCount "45" @default.
• W1816122400 countsByYear W18161224002015 @default.
• W1816122400 crossrefType "journal-article" @default.
• W1816122400 hasAuthorship W1816122400A5001359178 @default.
• W1816122400 hasAuthorship W1816122400A5003643368 @default.
• W1816122400 hasAuthorship W1816122400A5022511085 @default.
• W1816122400 hasAuthorship W1816122400A5028260119 @default.
• W1816122400 hasAuthorship W1816122400A5033181043 @default.
• W1816122400 hasAuthorship W1816122400A5035759347 @default.
• W1816122400 hasAuthorship W1816122400A5057832019 @default.
• W1816122400 hasAuthorship W1816122400A5063272996 @default.
• W1816122400 hasAuthorship W1816122400A5072098734 @default.
• W1816122400 hasConcept C112705442 @default.
• W1816122400 hasConcept C126322002 @default.
• W1816122400 hasConcept C126894567 @default.
• W1816122400 hasConcept C2776694085 @default.
• W1816122400 hasConcept C2777063308 @default.
• W1816122400 hasConcept C2780306776 @default.
• W1816122400 hasConcept C2780580376 @default.
• W1816122400 hasConcept C2780852908 @default.
• W1816122400 hasConcept C2781303535 @default.
• W1816122400 hasConcept C29730261 @default.
• W1816122400 hasConcept C71924100 @default.
• W1816122400 hasConcept C90924648 @default.
• W1816122400 hasConcept C98274493 @default.
• W1816122400 hasConceptScore W1816122400C112705442 @default.
• W1816122400 hasConceptScore W1816122400C126322002 @default.
• W1816122400 hasConceptScore W1816122400C126894567 @default.
• W1816122400 hasConceptScore W1816122400C2776694085 @default.
• W1816122400 hasConceptScore W1816122400C2777063308 @default.
• W1816122400 hasConceptScore W1816122400C2780306776 @default.
• W1816122400 hasConceptScore W1816122400C2780580376 @default.
• W1816122400 hasConceptScore W1816122400C2780852908 @default.
• W1816122400 hasConceptScore W1816122400C2781303535 @default.
• W1816122400 hasConceptScore W1816122400C29730261 @default.
• W1816122400 hasConceptScore W1816122400C71924100 @default.
• W1816122400 hasConceptScore W1816122400C90924648 @default.
• W1816122400 hasConceptScore W1816122400C98274493 @default.
• W1816122400 hasIssue "20" @default.
• W1816122400 hasLocation W18161224001 @default.
• W1816122400 hasOpenAccess W1816122400 @default.
• W1816122400 hasPrimaryLocation W18161224001 @default.
• W1816122400 hasRelatedWork W1855109513 @default.
• W1816122400 hasRelatedWork W2003487962 @default.
• W1816122400 hasRelatedWork W2031477213 @default.
• W1816122400 hasRelatedWork W2035090576 @default.
• W1816122400 hasRelatedWork W2072252734 @default.
• W1816122400 hasRelatedWork W2074629895 @default.
• W1816122400 hasRelatedWork W2098949345 @default.
• W1816122400 hasRelatedWork W2416950205 @default.
• W1816122400 hasRelatedWork W2421020884 @default.
• W1816122400 hasRelatedWork W2598391251 @default.
• W1816122400 hasVolume "53" @default.
• W1816122400 isParatext "false" @default.
• W1816122400 isRetracted "false" @default.
• W1816122400 magId "1816122400" @default.
• W1816122400 workType "article" @default.